New data from randomized trial dent HIV drug strategy against Covid-19

It’s not all good news coming out of the first round of clinical data investigating treatment options for Covid-19. In a new study published in the New England Journal of Medicine, researchers suggested that an HIV drug that had emerged as a promising candidate early on missed the clinical mark.